Skip to main content
. 2022 Feb 17;12:807189. doi: 10.3389/fonc.2022.807189

Table 3.

Univariate and multivariate analysis for PFS.

HR 95% CI p value
Univariate analysis
Age, ≥60/<60 years 0.781 0.355-1.718 0.5386
Early AFP response, yes/no 0.464 0.222-0.967 0.0404
Baseline AFP, ≥400/<400 ng/ml 1.414 0.681-2.935 0.3530
Ascites, yes/no 1.377 0.664-2.853 0.3897
Cirrhosis, yes/no 1.127 0.497-2.555 0.7746
Maximum tumor diameter, ≥10/<10 cm 0.420 0.143-1.235 0.1150
Number of tumors, solitary/multiple 0.793 0.332-1.893 0.6014
Extrahepatic metastasis, yes/no 1.585 0.633-3.972 0.3255
Portal vein thrombosis, yes/no 0.825 0.374-1.819 0.6338
BCLC stage, B/C 0.711 0.270-1.872 0.4903
ECOG PS, 0/1 0.431 0.265-0.897 0.0398
ALBI grade, 1/2 0.538 0.290-0.973 0.0462
Child-Pugh class, A/B 0.658 0.311-1.393 0.2742
Multivariate analysis
Age, ≥60/<60 years 0.535 0.191-1.499 0.2341
Early AFP response, yes/no 0.387 0.183-0.992 0.0154
ECOG PS, 0/1 0.489 0.411-0.976 0.0132
Extrahepatic metastasis, yes/no 1.659 0.525-3.517 0.5271
Portal vein thrombosis, yes/no 1.059 0.437-2.324 0.6574
ALBI grade, 1/2 0.457 0.269-0.963 0.0327

ALBI, albumin-bilirubin; AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio.